Physician profile
Roy Chen
NPI 1720248081
$1,042.07
in general payments reported to CMS, 2019-2025
16 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $74.41 · 2021: $263 · 2022: $320 · 2023: $14.88 · 2024: $129 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $271.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $270.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $245.75 | 2020-2022 | |
| Astrazeneca Pharmaceuticals Lp | $131.43 | 2021 | |
| Intera Oncology, INC | $128.84 | 2024 | Intera |
| Galvanize Therapeutics, INC | $127.25 | 2025 | Aliya System |
| Kite Pharma, INC. | $112.90 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $54.01 | 2019-2020 | |
| Mylan Institutional INC. | $46.41 | 2019-2020 | |
| Pfizer INC. | $36.77 | 2022 | |
| Eisai INC. | $36.04 | 2019 | |
| Cti Biopharma Corp. | $24.35 | 2022 | |
| Alnylam Pharmaceuticals INC. | $22.46 | 2021 | |
| Servier Pharmaceuticals LLC | $18.88 | 2021 | |
| Seagen INC. | $15.97 | 2019 | |
| Kerecis Limited | $14.88 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Emd Serono, INC. | $14.21 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roy Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.